AJANTA
PHARMA LTD
RESULTS
FOT Q2 FY 13-14
SEP
2013
Ajanta Pharma has
produced excellent Results for the second quarter ending Sep. 2013.
Total Income
has
gone up to Rs.280 Cr; compared to Rs.218 Cr in the preceding quarter ending
30.6.2013 (+28.44%); and compared to Rs.186 Cr in the corresponding quarter
ending Sep, 2012 (+50.54%). The increase in sales both sequentially and Year on
Year are quite impressive.
Total Expenditure has gone up to Rs.205 Cr; compared to Rs.176 Cr
in the preceding quarter ending 30.6.2013 (+16.48%); and compared to Rs.151 Cr
in the corresponding quarter ending Sep, 2012 (+35.76%). Though expenditure has
increased, it is proportionately MUCH
LESS than the increase in Total Income.
Net Profit
has
gone up to Rs.56 Cr; compared to Rs.33 Cr in the preceding quarter ending
30.6.2013 (+69.7%); and compared to Rs.22 Cr in the corresponding quarter
ending Sep, 2012 (+154.55%).The less than proportionate increase in expenditure
and impressive increase in Total income has contributed to an EXCELLENT and
Impressive improvement in margins and profit levels.
Equity has increased to Rs.17.67 Cr in Sep ,
13, compared to Rs.11.81 Cr in June 2013 – due to the Bonus shares issued by
the company in the ratio of 1 : 2 ( 1 Bonus
share for every 2 Eq shares Held).
Face Value
of
the Share is Rs.5.
Basic EPS(Rs) has gone up to Rs.15.88 in Sep,13 compared to Rs.9.26 in June 13 and
Rs.6.21 only in Sep,12.
Diluted EPS
(Rs) has gone up to Rs.15.86 in Sep,13,
compared to Rs.9.24 in June 13 and compared to Rs.6.21 only in Sep,12.
Diluted EPS
for
H.Y. Ending Sep,13 is Rs.25.14 compared to the HY ending Sep12 of Rs.11.77. The
annual EPS for Y.E. Mar,13 was Rs.28.71. Thus, the annualized EPS for FY 14
will be over Rs.50.3, which is quite impressive. The Market price after
declaration of results is Rs.840. On this basis, the PE ratio works out to
16.7. Considering its future prospects, the share can scale further heights. It
is a Good Buy for medium / long term Investors.
QUARTERLY RESUTLS
TABLE
|
Ajanta
Pharma
|
30.09.13
|
30.6.13
|
%Dif
QoQ
|
30.9.12
|
%Dif
YoY
|
|
|
Total
Income
|
280
|
218
|
28.44
|
186
|
50.54
|
|
|
Total
Expdr
|
205
|
176
|
16.48
|
151
|
35.76
|
|
|
Net
Profit
|
56
|
33
|
69.7
|
22
|
154.55
|
|
|
Equity
|
17.67
|
11.81
|
49.62
|
11.8
|
49.75
|
|
|
FV
|
5
|
5
|
0
|
5
|
0
|
|
|
Basic
EPS(rs)
|
15.88
|
9.26
|
71.49
|
6.21
|
155.72
|
|
|
Diluted
EPS (Rs)
|
15.86
|
9.24
|
71.65
|
6.21
|
155.39
|
|
HALF YEARLY RESULTS
TABLE
|
Ajanta
Pharma
|
hy30.9.13
|
Hy30.9.12.
|
%Dif
YoY
|
ye31.3.13
|
|
|
Total
Income
|
498
|
360
|
38.33
|
839
|
|
|
Total
Expdr
|
381
|
297
|
28.28
|
665
|
|
|
Net
Profit
|
88
|
41
|
114.63
|
101
|
|
|
Equity
|
17.67
|
11.8
|
49.75
|
11.8
|
|
|
FV
|
5
|
5
|
0
|
5
|
|
|
Basic
EPS(rs)
|
25.14
|
11.81
|
112.87
|
28.78
|
|
|
Diluted
EPS (Rs)
|
25.1
|
11.77
|
113.25
|
28.71
|
|
Excerpts
from Company Release :
. Revenue from operations at Rs.280 crore
(Rs.186 crore), growth of 50% over Q2 last year
. EBITDA at Rs.84 crore (Rs.43 crore), growth
of 95% over Q2 last year
. EBITDA margin at 30% against 23% of Q2
last year
. Profit after Tax at Rs. 56 crore (Rs.22 crore), growth of 155%
over Q2 last
year
. Exports contributed 64% of the total operating
income for the quarter
Mr.Yogesh Agrawal, Managing Director, Ajanta
Pharma Limited, said "we are
Pleased with healthy results for the quarter
driven by India and emerging markets. We remain focused on select specialty therapeutic
segments in India and select geographies in overseas market. We continue to stretch
boundaries of excellence and building quality business on the already laid
Strong foundation with focus on growing
sales and profitability consistently."
Company filed 3 more ANDAs with US FDA during
the quarter taking total tally to'18 ANDAs (2 approved and 16 awaiting approval)
* *
* E P S *
* *
No comments:
Post a Comment